Source: Eur Respir J 2003; 21: 483-488
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Schon T., Elias D., Moges F., Melese E., Tessema T., Stendahl O., Britton S., Sundqvist T.. Arginine as an adjuvant to chemotherapy improves clinical outcome in active tuberculosis. Eur Respir J 2003; 21: 483-488

Member's Comments

No comment yet.

Related content which might interest you: Re-activation of bovine tuberculosis in a patient treated with infliximab Source: Eur Respir J 2008; 32: 229-231 Year: 2008 Isoniazid protection and risk of tuberculosis in patients who used anti tumor necrosis factor-alpha treatment Source: Annual Congress 2007 - New perspectives and old problems in diagnosing tuberculosis infection and disease Year: 2007 Inhaled IFN-γ for persistent nontuberculous mycobacterial pulmonary disease due to functional IFN-γ deficiency Source: Eur Respir J 2004; 24: 367-370 Year: 2004 A novel TNF inhibitor does not compromise host immunity to mycobacterium tuberculosis and BCG infections and still protects from hepatitis Source: Annual Congress 2009 - Clinical immunology of tuberculosis Year: 2009 LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement Source: Eur Respir J 2009; 33: 956-973 Year: 2009 Interferon-? release assays for the diagnosis of latent Mycobacterium tuberculosis infection Source: Eur Respir J 2011; 38: 1238-1239 Year: 2011 QuantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases Source: Eur Respir J 2009; 33: 586-593 Year: 2009 Clinical management of tuberculosis and HIV-1 co-infection Source: Eur Respir J 2010; 36: 1460-1481 Year: 2010 Screening for latent tuberculosis before tumour necrosis factor antagonist therapy Source: Eur Respir J 2015; 45: 1512-1513 Year: 2015 Screening for latent tuberculosis before tumour necrosis factor antagonist therapy Source: Eur Respir J 2015; 45: 1510-1512 Year: 2015 Cost-effectiveness of interferon-γ release assay testing for the treatment of latent tuberculosis Source: Eur Respir J 2007; 30: 321-332 Year: 2007 Interferon-gamma release assays for the diagnosis of latent Mycobacterium tuberculosis infection Source: Eur Respir J 2011; 38: 1237-1238 Year: 2011 Mycobacterium tuberculosis bacteremia in reactivation tuberculosis patients without human immunodeficiency virus infection Source: Eur Respir J 2005; 26: Suppl. 49, 690s Year: 2005 Response to Rv2628 latency antigen associates with cured tuberculosis and remote infection Source: Eur Respir J 2010; 36: 135-142 Year: 2010 High-dose nitric oxide as a potential new therapeutic agent against Mycobacterium abscessus. Source: International Congress 2018 – New therapies for respiratory infections: experimental and translational studies Year: 2018 The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement Source: Eur Respir J 2010; 36: 1185-1206 Year: 2010 Treatment of latent infection with Mycobacterium tuberculosis: update 2010 Source: Eur Respir J 2011; 37: 690-711 Year: 2011 Comparison of effector T-cell responses in patients with active TB disease compared to latent TB infection Source: Annual Congress 2007 - New perspectives and old problems in diagnosing tuberculosis infection and disease Year: 2007 Clinical and laboratory features of Mycobacterium avium complex infection in comparison with infection, caused by Mycobacterium tuberculosis, in HIV-infected patients Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection II Year: 2019 TB in the immunocompromised host Source: Eur Respir Mon 2012; 58: 230-241 Year: 2012